Document is current

Article History

Received: 9 April 2025

Accepted: 31 May 2025

First Online: 10 June 2025

Declarations

:

: MB received speaker honoraria from GE healthcare, Roche, and LMI and is an advisor of LMI. A.W.S., A.M., N.K. and G.N.B. are employed by LMI. G.H. received research support from GE Healthcare and Neuropore; has ongoing research collaborations with Orion and Prothena; serves as a consultant for AbbVie, AlzProtect, Asceneuron, Biogen, Biohaven, Lundbeck, Novartis, Roche, Sanofi, UCB; received honoraria for scientific presentations from AbbVie, Biogen, Roche, Teva, UCB, and Zambon; and holds a patent on PERK Activation for the Treatment of Neurodegenerative Diseases (PCT/EP2015/068734). No other potential conflict of interest relevant to this article was reported.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (LMU Munich—application number 17–569) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all patients. All patients provided informed written consent to PET imaging. The study was conducted in accordance with the principles of the Declaration of Helsinki, and approval for scientific data analysis was obtained from the local ethics committee (application number 17–569).